Clinical Trial

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-03
notable Trial sites reduced: 120 -> 115 locations 2026-07-03
Trial Details
NCT Number NCT07645924
Lead Sponsor Kallyope Inc.
Conditions Migraine
Enrollment 1,800 participants
Start Date 2026-07-01
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-05